Lackner Mark 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4
Lackner Mark
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-01-02+60,000→ 60,000 totalExercise: $15.99Exp: 2034-01-02→ Common Stock (60,000 underlying) - Award
Common Stock
2024-01-02+40,000→ 56,313 total
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer.
- [F2]The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.